Mind-body therapies like meditation, psychotherapy, and deep breathing may help reduce stress levels, potentially reducing ...

Allergy and immunology lost a pioneer last summer with the death of Marcus Maurer, MD, executive director of the Institute of Allergology at Charité University Medicine, Berlin. Maurer was an author ...

Conclusion: Treating chronic idiopathic urticaria with levocetirizine is a dominant strategy for society since it is more effective (in terms of pruritus-free days gained) and less costly than ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Sometimes, your backside can itch for no particular reason, something medical experts call idiopathic pruritis ... especially if it's from a chronic health issue. But there are some things you ...

The biotech had previously been testing the oral itch medication in individuals with advanced chronic kidney disease ... which is in a phase 2 trial for idiopathic pulmonary fibrosis and a ...

Leerink Partners analyst Faisal Khurshid reiterated a Buy rating on Trevi Therapeutics (TRVI – Research Report) on January 10 and set a price ...

Cara Therapeutics has developed an IV formulation of difelikefalin, which is approved for the treatment of moderate-to-severe pruritus in adults undergoing hemodialysis due to advanced chronic ...

Vixarelimab (KPL-716) is under development for the treatment of pruritus, prurigo nodularis, plaque psoriasis (psoriasis vulgaris), lichen simplex chronicus (neurodermatitis), erosive oral lichen ...

According to GlobalData, Phase I drugs for Systemic-Onset Juvenile Idiopathic Arthritis (Still ... in treating various diseases including chronic spontaneous urticaria, atopic dermatitis (AD), ...

People who have this medical condition develop hives (welts on their skin that often itch) when exposed to the cold ... “Rupatadine 20 mg and 40 mg are effective in reducing the symptoms of chronic ...

Imran Alibhai, Ph.D., Chief Executive Officer of Tvardi Therapeutics, stated, “As we approach meaningful value inflection points next year, including two Phase 2 readouts of our lead program in ...